ADC FOR A TREATMENT CONCOMITANT WITH OR SUBSEQUENT TO DOCETAXEL
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 14, 2022
app pub date -
May 6, 2020
filing date -
May 6, 2019
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to an ADC having the following formula (I) in which Ab is an anti-IGF1R antibody characterized in that it comprises light chain CDRs of sequences SEQ ID Nos. 9, 5 and 11, respectively, and heavy chain CDRs of sequences SEQ ID Nos. 7, 2 and 3, respectively, and n is between 1 and 12, for use in the treatment of proliferative diseases, such as cancer, characterized in that the ADC is administered concomitantly with or subsequent to docetaxel.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully